Burroughs Wellcome Co. (BW) of Research Triangle Park has expanded its efforts in immunotherapy by purchasing the rights to develop several monoclonal antibodies and related technologies from the Immunoconjugates Division of Sterling Winthrop Pharmaceuticals Research Division, New York.
The deal includes the rights to at least five monoclonal antibodies for oncology, a technology that makes possible delivery of multiple copies of an agent to a tumor or other target, and access to two technologies that bind radioisotopes to antibodies. BW will also receive cell lines and other related biotechnology tools and all data accumulated on the five compounds to date.
The …
No comments:
Post a Comment